Alan H.B. Wu, PhD
Research and Clinical Interests
My area of research is focused on “personalized therapeutics,” i.e., the use of biomarkers to determine proper selection and dosing of drugs to maximize efficacy and minimize adverse reactions. Many future drugs will require biomarker testing prior to use on individual patients and clinical trials are needed to validate their use. In the area of pharmacogenomics, we are interested in drug dosing studies for warfarin, irinotecan, tamoxifen, phenytoin and lipid lowering drugs. We are also performing research on validating novel protein markers for cardiovascular diseases such as stroke, acute coronary syndromes and heart failure.
Selected Publications
- Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AHB, et al. Rapid measurement of B-type natriruetic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-7.
- Wu AHB, Broussard LA, Hoffman RS, et al. National Academy of Clinical Biochemistry. Laboratory Medicine Practice Guidelines. Recommendations for the Use of Laboratory Tests to Support the Impaired and Overdosed Patients from the Emergency Department. Clin Chem 2003;49:357-79.
- Wu AHB, Smith AC, Mather JF, Duncan B, White CM, Ahlberg A, McGill C, Heller H. Biological variation for NT-pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003,92:628-31.
- Wu AHB, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004,6:355-8.
- Wu AHB. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biological variation in interpretation of results. Am Heart J. 2006, accepted.
Selected Awards
- 2002 American Assoc for Clinical Chemistry Outstanding Contributions to Education Award
- 2005 IVD Technology's Top Ten Persons in the IVD Industry
- 2005 AACC Connecticut Valley Section, Seligson-Golden Award
- 2006 Meyer Bodanski Visiting Professor of Pathology, University of Texas Medical Branch
- Professor Laboratory Medicine, Chief, Clinical Chemistry Laboratory, SFGHTC
- Laboratory Medicine
- Clinical Chemistry
Specialty Area
- Cardiac biomarkers
- Analytical and toxicology
- Pharmacogenomics
Contact Information
- wualan@
labmed2.ucsf.edu - Phone: (415) 206-3540
- Fax: (415) 206-3045
- San Francisco General Hospital & Trauma Center
- 1001 Potrero Ave., Room 2M27
- San Francisco, CA 94110
Other UCSF Organizational Association(s)
Graduate faculty
- Pharmaceutical Science and Pharmacogenomics
Hospital Affiliation(s)
- San Francisco General Hospital & Trauma Center